On a day when traditional snack giants are bracing for the “snackpocalypse,” one corner of the confectionery world is breathing a sigh of minty relief. As of Thursday, April 30, 2026, the financial world is digesting a surprising revelation from Hershey’s first-quarter earnings call: while consumers may be putting down the chocolate bars, they are picking up the gum at record rates.
The catalyst? The meteoric rise of GLP-1 receptor agonists like Ozempic, Wegovy, and the recently approved oral variants that have flooded the market in early 2026.
The Ice Breakers Phenomenon
Hershey CEO Kirk Tanner stunned analysts this morning by reporting an 8% increase in sales for the company’s Ice Breakers brand. In an era where total calorie consumption among GLP-1 users has plummeted by as much as 30%, a growth figure in the high single digits for a “snack” category is practically unheard of.
“We are seeing a significant functional snacking tailwind,” Tanner noted during the call. “The adoption of GLP-1 medications is creating a new type of consumer—one who prioritizes oral freshness and hydration over traditional indulgence.”
This “functional tailwind” is the industry’s polite term for a side effect that has become a viral sensation: “Ozempic Breath.” As millions of Americans transition to these medications—with projections hitting 30 million users by 2030—the pharmaceutical side effects are rewriting the P&L statements of the world’s largest food companies.
The Biology of the “Fresh” Surge
To understand why gum is flying off the shelves, one must examine the biological effects of semaglutide and tirzepatide. Medical professionals, including Dr. Neha Lalani, have noted that GLP-1 drugs frequently cause xerostomia, or chronic dry mouth. Because these medications slow gastric emptying and alter metabolic signals, patients often experience reduced saliva production.
Saliva is the mouth’s natural defense against bacteria. Without it, the mouth becomes a breeding ground for the microbes that cause halitosis. Furthermore, as the body enters a state of rapid fat burning—akin to ketosis—users often report a “metallic” or “fruity” smell on their breath, colloquially known as “Ozempic Breath.”
“It is a perfect storm for the oral care industry,” says a recent report from URBN Dental. The analysis found that searches for “dry mouth” and “GLP-1 side effects” reached an all-time high in March 2026, moving in lockstep with the expansion of drug prescriptions. For the consumer, the solution is simple and accessible: a pack of sugar-free gum or a tin of extra-strength mints.
The Death of the “Auto-Pilot” Snack
The rise of gum is the silver lining in a cloud that has been hanging over the snack industry since 2024. According to data from Numerator and a landmark study from Cornell University, households with at least one GLP-1 user reduce their total grocery spending by an average of 5.3% within the first six months. For high-income households, that drop is even steeper, reaching 8%.
Categories like savory snacks (chips, crackers) have seen volume declines of nearly 10-11%. The “reward response” in the brain—the hit of dopamine one gets from a salty potato chip—is effectively blunted by the medication.
“GLP-1s take the joy out of ‘mindless’ grazing,” explains Sascha Ammesdoerfer, Director of Market Intelligence at Videojet. “But they haven’t removed the social need for oral hygiene or the physical discomfort of a dry mouth. That is why we are seeing this divergence: calories are down, but ‘function’ is up.”
A Strategic Pivot: “GLP-1 Friendly” Everything
The industry isn’t just watching from the sidelines; it is rebranding in real-time. In early 2026, the “GLP-1 Friendly” label has become the new “Gluten-Free.”
Nestle was among the first to move, launching its “Vital Pursuit” line of frozen meals specifically designed for those on weight-loss medications. After initial success, the company added “GLP-1 Friendly” stickers to its packaging in late 2025. Today, Conagra Brands has followed suit, placing the label on 26 of its Healthy Choice frozen meals.
Even retailers are getting in on the action. Kroger and Walmart are now using purchase data to identify “GLP-1 shopper personas.” These shoppers are being steered away from the candy aisle and toward high-protein dairy, hydration-boosting beverages, and, of course, the strategically placed gum and mint displays at checkout.
The Oral Frontier: New Pills, New Problems
The demand for gum is expected to accelerate through the remainder of 2026. In late 2025, the FDA approved the first wave of next-generation oral GLP-1 pills. Unlike the injectables, which required weekly shots, these daily tablets are expected to dramatically increase market penetration among patients who were previously needle-phobic.
J.P. Morgan senior analyst Chris Schott predicts that the launch of these oral options, coupled with recent moves by the Trump administration to cap Medicare out-of-pocket costs for weight-loss drugs at $50 through the BALANCE pilot program, will cause a “second wave” of adoption.
“As the barrier to entry drops, the ‘Ozempic Mouth’ phenomenon will scale,” Schott says. “This isn’t just a niche health issue anymore; it’s a mass-market behavioral shift.”
The “Churn” Factor
However, some analysts caution that the gum boom might have a shelf life. AlixPartners points out that a meaningful share of users—well over half of those taking the drugs for non-diabetic weight loss—discontinue use within a year due to costs or side effects.
When users stop the medication, their “snacking “auto-pilot often returns. Data shows that households that discontinue GLP-1s often revert to pre-adoption spending patterns, with candy and chocolate being the first categories to rebound.
“The gum industry is enjoying a moment of structural growth,” says Jeff Perry, VP at Catalina. “But the real winners will be the brands that can transition these users from ‘functional’ gum chewers back into ‘lifestyle’ snackers if and when they come off the medication.”
Conclusion: A New Era of Consumption
As we hit the midway point of 2026, the snack industry is no longer the monolith it once was. The divergence between “calorie-dense” and “function-dense” products is the new reality.
For companies like Hershey, the 8% growth in Ice Breakers is more than just a quarterly win; it is a blueprint for survival in a GLP-1 world. By leaning into the side effects of the world’s most popular drugs, the confectionery industry has found a way to stay relevant, one minty breath at a time.
Sources Used and Links:
- J.P. Morgan: How Supply and Demand for Weight Loss Drugs is Playing Out in 2026 https://www.jpmorgan.com/insights/global-research/current-events/obesity-drugs
- CBS News: “Ozempic breath” is boosting Hershey’s sales of mints and gum https://www.cbsnews.com/news/ozempic-breath-glp-1-side-effect-hershey-minte-sales/
- Videojet: How GLP-1 Drugs Like Ozempic are Reshaping the Food Industry https://www.videojet.com/us/homepage/resources/learn/glp-1-food-industry-impact.html
- Cornell Chronicle: Ozempic is changing the foods Americans buy https://news.cornell.edu/stories/2025/12/ozempic-changing-foods-americans-buy
- URBN Dental: America’s Weight-Loss Drugs Boom: The Growing Link Between GLP-1 Use and Oral Health Concerns https://urbndental.com/americas-weight-loss-drugs-boom-the-growing-link-between-glp-1-use-and-oral-health-concerns/
- Red Bud Dental: ‘Ozempic Mouth’ Is Real — Here’s What Round Rock Patients Need to Know https://familyroundrockdentist.com/ozempic-mouth-is-real-heres-what-round-rock-patients-on-glp-1-medications-need-to-know/
- Associated Press (AP): Food companies are targeting users of weight-loss drugs with ‘GLP-1 Friendly’ labels https://apnews.com/article/weightloss-drugs-nutrition-frozen-meals-glp1-5bb5dfaae3778b1968c1793326e8ba73
- Catalina: How Retailers and CPG Brands Can Unlock Growth in the Era of GLP-1 Medications https://www.catalina.com/perspectives-blog/blog-how-retailers-and-cpg-brands-can-unlock-growth-in-the-era-of-glp-1
- Marriner Marketing: How Will GLP-1s Impact the Food and Beverage Industry in 2026? https://www.marriner.com/blog/how-will-glp-1s-impact-the-food-and-beverage-industry-in-2026/
- AlixPartners: GLP-1 and the snack sector: Disruptive trend, not existential threat https://www.alixpartners.com/insights/102mndi/glp-1-and-the-snack-sector-disruptive-trend-not-existential-threat/
Disclaimer
Artificial Intelligence Disclosure & Legal Disclaimer
AI Content Policy.
To provide our readers with timely and comprehensive coverage, South Florida Reporter uses artificial intelligence (AI) to assist in producing certain articles and visual content.
Articles: AI may be used to assist in research, structural drafting, or data analysis. All AI-assisted text is reviewed and edited by our team to ensure accuracy and adherence to our editorial standards.
Images: Any imagery generated or significantly altered by AI is clearly marked with a disclaimer or watermark to distinguish it from traditional photography or editorial illustrations.
General Disclaimer
The information contained in South Florida Reporter is for general information purposes only.
South Florida Reporter assumes no responsibility for errors or omissions in the contents of the Service. In no event shall South Florida Reporter be liable for any special, direct, indirect, consequential, or incidental damages or any damages whatsoever, whether in an action of contract, negligence or other tort, arising out of or in connection with the use of the Service or the contents of the Service.
The Company reserves the right to make additions, deletions, or modifications to the contents of the Service at any time without prior notice. The Company does not warrant that the Service is free of viruses or other harmful components.
